Prediction of treatment response in patients with locally advanced cervical cancer using midtreatment PET/MRI during concurrent chemoradiotherapy
Jazyk angličtina Země Německo Médium print-electronic
Typ dokumentu srovnávací studie, časopisecké články
Grantová podpora
CZ.02.1.01/0.0/0.0/17_048/0007280)
Lékařská Fakulta v Plzni, Univerzita Karlova
PubMed
33492444
DOI
10.1007/s00066-020-01740-7
PII: 10.1007/s00066-020-01740-7
Knihovny.cz E-zdroje
- Klíčová slova
- Cervical cancer, Magnetic resonance imaging, Positron emission tomography, Treatment response, Uterovaginal brachytherapy,
- MeSH
- alkylační protinádorové látky terapeutické užití MeSH
- brachyterapie MeSH
- chemoradioterapie * MeSH
- cisplatina terapeutické užití MeSH
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- lymfatické metastázy MeSH
- magnetická rezonanční tomografie * MeSH
- multimodální zobrazování * MeSH
- nádory děložního čípku diagnostické zobrazování metabolismus patologie terapie MeSH
- ozařování lymfatického systému MeSH
- plocha pod křivkou MeSH
- počítačové zpracování obrazu MeSH
- pozitronová emisní tomografie * MeSH
- prognóza MeSH
- radioterapie s modulovanou intenzitou MeSH
- ROC křivka MeSH
- senioři MeSH
- spinocelulární karcinom diagnostické zobrazování metabolismus patologie terapie MeSH
- staging nádorů metody MeSH
- tumor burden MeSH
- výsledek terapie MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- srovnávací studie MeSH
- Názvy látek
- alkylační protinádorové látky MeSH
- cisplatina MeSH
PURPOSE: We aimed to find metabolic, functional or morphological characteristics of the tumor predicting failure to achieve complete metabolic remission (CMR) by the midtreatment PET/MRI (positron emission tomography/magnetic resonance imaging) in cervical cancer patients. METHODS: We evaluated 66 patients treated between August 2015 and November 2019 who underwent pretreatment staging, subsequent midtreatment evaluation, and definitive restaging 3 months after completing the whole treatment, all using PET/MRI. The pretreatment parameters (pre-SUVmax, pre-SUVmean, pre-MTV, pre-MTV‑S, pre-TLG, pre-TLG‑S [SUV: standard uptake value, MTV: metabolic tumor volume, TLG: total lesion glycolysis]), and the midtreatment parameters at week 5 during chemoradiotherapy (mid-SUVmax, mid-SUVmean, mid-MTV, mid-MTV‑S, mid-TLG and mid-TLG-S) were recorded. The value of ADC (apparent diffusion coefficient) was also measured. Furthermore, we recorded absolute and relative changes in all parameters-∆ and ∆%. We divided the whole group of patients into "responders" (CMR) and "non-responders" (non-CMR), and compared them on the basis of the parameters from pre-PET/MRI and mid-PET/MRI. RESULTS: A statistically significant difference in the evaluated parameters between responders and non-responders was found for the following parameters: mid-MTV, mid-TLG, mid-TLG‑S, mid-MTV‑S, mid-tumor size, and ∆%SUVmax. According to the ROC (receiver operating characteristic) analysis, mid-MTV‑S showed the best albeit moderate discrimination ability for the prediction of non-CMR. Significant mutual correlations of all variables, in particular between mid-MTV‑S and mid-TLG‑S and between mid-MTV and mid-TLG, were found (all p < 0.05). CONCLUSION: Our study confirmed that when using the midtreatment PET/MRI we are able to identify metabolic parameters having the discrimination ability for the prediction of non-CMR. In particular mid-MTV‑S, mid-MTV, mid-tumor size, mid-TLG‑S, mid-TLG and ∆%SUVmax.
Zobrazit více v PubMed
Ferlay J, Colombet M, Soerjomataram I et al (2019) Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer 144(8):1941–1953 DOI
Chemoradiotherapy for Cervical Cancer Meta-Analysis Collaboration (2008) Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: a systematic review and meta-analysis of individual patient data from 18 randomized trials. J Clin Oncol 26(35):5802–5812 DOI
Pecorelli S, Zigliani L, Odicino F (2009) Revised FIGO staging for carcinoma of the cervix. Int J Gynaecol Obstet 105(2):107–108 DOI
Grant P, Sakellis C, Jacene HA (2014) Gynecologic oncologic imaging with PET/CT. Semin Nucl Med 44(6):461–478 DOI
Choi HJ, Ju W, Myung SK, Kim Y (2010) Diagnostic performance of computer tomography, magnetic resonance imaging, and positron emission tomography or positron emission tomography/computer tomography for detection of metastatic lymph nodes in patients with cervical cancer: meta-analysis. Cancer Sci 101(6):1471–1479 DOI
Kitajima K, Suenaga Y, Ueno Y et al (2014) Fusion of PET and MRI for staging of uterine cervical cancer: comparison with contrast-enhanced (18)F-FDG PET/CT and pelvic MRI. Clin Imaging 38(4):464–469 DOI
Sarabhai T, Tschischka A, Stebner V et al (2018) Simultaneous multiparametric PET/MRI for the assessment of therapeutic response to chemotherapy or concurrent chemoradiotherapy of cervical cancer patients: preliminary results. Clin Imaging 49:163–168 DOI
Grueneisen J, Schaarschmidt BM, Heubner M et al (2015) Integrated PET/MRI for whole-body staging of patients with primary cervical cancer: preliminary results. Eur J Nucl Med Mol Imaging 42(12):1814–1824 DOI
Haie-Meder C, Pötter R, Van Limbergen E et al (2005) Gynaecological (GYN) GEC-ESTRO working group. Recommendations from gynaecological (GYN) GEC-ESTRO working group (I): concepts and terms in 3D image based 3D treatment planning in cervix cancer brachytherapy with emphasis on MRI assessment of GTV and CTV. Radiother Oncol 74(3):235–245 DOI
Pötter R, Haie-Meder C, Van Limbergen E, GEC ESTRO Working Group et al (2006) Recommendations from gynaecological (GYN) GEC ESTRO working group (II): concepts and terms in 3D image-based treatment planning in cervix cancer brachytherapy-3D dose volume parameters and aspects of 3D image-based anatomy, radiation physics, radiobiology. Radiother Oncol 78(1):67–77 DOI
Viswanathan AN, Thomadsen B, American Brachytherapy Society Cervical Cancer Recommendations Committee, American Brachytherapy Society (2012) American brachytherapy society consensus guidelines for locally advanced carcinoma of the cervix. Part I: general principles. Brachytherapy 11(1):33–46 DOI
Viswanathan AN, Beriwal S, De Los Santos JF, American Brachytherapy Society et al (2012) American brachytherapy society consensus guidelines for locally advanced carcinoma of the cervix. Part II: high-dose-rate brachytherapy. Brachytherapy 11(1):47–52 DOI
Vojtíšek R, Sukovská E, Baxa J et al (2019) Late side effects of 3T MRI-guided 3D high-dose rate brachytherapy of cervical cancer: institutional experiences. Strahlenther Onkol 195(11):972–981 DOI
Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45(2):228–247 DOI
O JH, Lodge MA, Wahl RL (2016) Practical PERCIST: a simplified guide to PET response criteria in solid tumors 1.0. Radiology 280(2):576–584 DOI
Agresti A, Coull BA (1998) Approximate is better than “exact” for interval estimation of binomial proportions. Am Stat 52:119–126
Herrera FG, Breuneval T, Prior JO, Bourhis J, Ozsahin M (2016) [(18)F]FDG-PET/CT metabolic parameters as useful prognostic factors in cervical cancer patients treated with chemo-radiotherapy. Radiat Oncol 11:43 DOI
Liu FY, Su TP, Wang CC et al (2018) Roles of posttherapy DOI
Poetsch N, Sturdza A, Aust S et al (2019) The value of pretreatment serum butyrylcholinesterase level as a novel prognostic biomarker in patients with cervical cancer treated with primary (chemo-)radiation therapy. Strahlenther Onkol 195(5):430–440 DOI
Liu FY, Lai CH, Yang LY et al (2016) Utility of (18)F-FDG PET/CT in patients with advanced squamous cell carcinoma of the uterine cervix receiving concurrent chemoradiotherapy: a parallel study of a prospective randomized trial. Eur J Nucl Med Mol Imaging 43(10):1812–1823 DOI
Scher N, Castelli J, Depeursinge A et al (2018) ( DOI
Yoo J, Choi JY, Moon SH et al (2012) Prognostic significance of volume-based metabolic parameters in uterine cervical cancer determined using 18F-fluorodeoxyglucose positron emission tomography. Int J Gynecol Cancer 22(7):1226–1233 DOI
Kidd EA, Siegel BA, Dehdashti F, Grigsby PW (2007) The standardized uptake value for F‑18 fluorodeoxyglucose is a sensitive predictive biomarker for cervical cancer treatment response and survival. Cancer 110(8):1738–1744 DOI
Onal C, Guler OC, Reyhan M, Yapar AF (2015) Prognostic value of 18F-fluorodeoxyglucose uptake in pelvic lymph nodes in patients with cervical cancer treated with definitive chemoradiotherapy. Gynecol Oncol 137(1):40–46 DOI
Akkas BE, Demirel BB, Dizman A, Vural GU (2013) Do clinical characteristics and metabolic markers detected on positron emission tomography/computerized tomography associate with persistent disease in patients with in-operable cervical cancer? Ann Nucl Med 27(8):756–763 DOI
Chung HH, Kim JW, Han KH et al (2011) Prognostic value of metabolic tumor volume measured by FDG-PET/CT in patients with cervical cancer. Gynecol Oncol 120(2):270–274 DOI
Yilmaz B, Dağ S, Ergul N, Çermik TF (2019) The efficacy of pretreatment and after treatment 18F-FDG PET/CT metabolic parameters in patients with locally advanced squamous cell cervical cancer. Nucl Med Commun 40(3):219–227 DOI
Son SH, Jeong SY, Chong GO et al (2018) Prognostic value of pretreatment metabolic PET parameters in cervical cancer patients with metabolic complete response after concurrent chemoradiotherapy. Clin Nucl Med 43(9):e296–e303 DOI
Hong JH, Min KJ, Lee JK et al (2016) Prognostic value of the sum of metabolic tumor volume of primary tumor and lymph nodes using 18F-FDG PET/CT in patients with cervical cancer. Medicine 95(9):e2992 DOI
Hong JH, Tsai CS, Lai CH et al (2004) Recurrent squamous cell carcinoma of cervix after definitive radiotherapy. Int J Radiat Oncol Biol Phys 60(1):249–257 DOI
Rose PG, Java J, Whitney CW et al (2015) Nomograms predicting progression-free survival, overall survival, and pelvic recurrence in locally advanced cervical cancer developed from an analysis of identifiable prognostic factors in patients from NRG oncology/gynecologic oncology group randomized trials of chemoradiotherapy. J Clin Oncol 33(19):2136–2142 DOI
Schwarz JK, Siegel BA, Dehdashti F, Grigsby PW (2007) Association of posttherapy positron emission tomography with tumor response and survival in cervical carcinoma. JAMA 298(19):2289–2295 DOI
Siva S, Deb S, Young RJ et al (2015) DOI
Schwarz JK, Grigsby PW, Dehdashti F, Delbeke D (2009) The role of 18F-FDG PET in assessing therapy response in cancer of the cervix and ovaries. J Nucl Med 50(1):64S–73S DOI
Ferrandina G, Petrillo M, Restaino G et al (2012) Can radicality of surgery be safely modulated on the basis of MRI and PET/CT imaging in locally advanced cervical cancer patients administered preoperative treatment? Cancer 118(2):392–403 DOI
Su TP, Lin G, Huang YT et al (2018) Comparison of positron emission tomography/computed tomography and magnetic resonance imaging for posttherapy evaluation in patients with advanced cervical cancer receiving definitive concurrent chemoradiotherapy. Eur J Nucl Med Mol Imaging 45(5):727–734 DOI
Crandall JP, Fraum TJ, Lee M et al (2020) Repeatability of PubMed DOI
Oh D, Lee JE, Huh SJ et al (2013) Prognostic significance of tumor response as assessed by sequential 18F-fluorodeoxyglucose-positron emission tomography/computed tomography during concurrent chemoradiation therapy for cervical cancer. Int J Radiat Oncol Biol Phys 87(3):549–554 DOI
Xu C, Sun H, Du S, Xin J (2019) Early treatment response of patients undergoing concurrent chemoradiotherapy for cervical cancer: an evaluation of integrated multi-parameter PET-IVIM MR. Eur J Radiol 117:1–8 DOI
Gao S, Du S, Lu Z et al (2020) Multiparametric PET/MR (PET and MR-IVIM) for the evaluation of early treatment response and prediction of tumor recurrence in patients with locally advanced cervical cancer. Eur Radiol 30(2):1191–1201 DOI
